KalVista Pharmaceuticals, Inc. (KALV) financial statements (2021 and earlier)

Company profile

Business Address 55 CAMBRIDGE PARKWAY
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End April 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5068101513154
Cash and cash equivalents181632513154
Short-term investments335269   
Receivables   73 
Other undisclosed current assets122115111
Total current assets:6389116593455
Noncurrent Assets
Operating lease, right-of-use asset22
Property, plant and equipment222201
Restricted cash and investments     0
Other noncurrent assets0000 1
Total noncurrent assets:443202
TOTAL ASSETS:6693118613457
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities678533
Accounts payable123111
Accrued liabilities556321
Debt 100 1
Deferred revenue and credits  0
Contract with customer, liability10
Other undisclosed current liabilities1  18  
Total current liabilities:78182334
Noncurrent Liabilities
Long-term debt and lease obligation11 0 3
Long-term debt, excluding current maturities     3
Capital lease obligations 0  
Operating lease, liability11
Liabilities, other than long-term debt  3  0
Deferred revenue and credits  0
Contract with customer, liability3
Other undisclosed noncurrent liabilities(1)  11  
Total noncurrent liabilities:11311 3
Total liabilities:89213437
Stockholders' equity
Stockholders' equity attributable to parent598497273149
Common stock000000
Additional paid in capital21320719110090122
Accumulated other comprehensive loss(1)(2)(2)(1)(3) 
Accumulated deficit(153)(122)(92)(72)(56)(73)
Total stockholders' equity:598497273149
TOTAL LIABILITIES AND EQUITY:6693118613457

Income statement (P&L) ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
12/31/2015
Revenue, net 20
Gross profit:41316820
Operating expenses(53)(53)(46)(27)(24)(21)
Operating loss:(49)(41)(30)(19)(22)(21)
Nonoperating income (expense)1111934(4)
Investment income, nonoperating121000
Foreign currency transaction gain (loss), before tax0(0)0(2)1 
Other nonoperating income10108421
Interest and debt expense     (3)
Loss from continuing operations before income taxes:(38)(29)(21)(16)(19)(28)
Income tax expense (benefit) 0(0)   
Other undisclosed income from continuing operations0     
Net loss:(38)(29)(21)(16)(19)(28)
Other undisclosed net income attributable to parent     3
Net loss available to common stockholders, diluted:(38)(29)(21)(16)(19)(25)

Comprehensive Income ($ in millions)

1/31/2021
TTM
4/30/2020
4/30/2019
4/30/2018
4/30/2017
12/31/2015
Net loss:(38)(29)(21)(16)(19)(28)
Other comprehensive income1     
Other undisclosed comprehensive loss(1)     
Comprehensive loss:(38)(29)(21)(16)(19)(28)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(1)2(3) 
Comprehensive loss, net of tax, attributable to parent:(38)(29)(22)(14)(21)(28)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: